A phase II study of AT9283, an aurora kinase inhibitor, in patients with relapsed or refractory multiple myeloma: NCIC clinical trials group IND.191. Issue 6 (2nd June 2016) - Hay, Annette E.; Murugesan, Alli; DiPasquale, Ashley M.; Kouroukis, Tom; Sandhu, Irwindeep; Kukreti, Vishal; Bahlis, Nizar J.; Lategan, Johan; Reece, Donna E.; Lyons, John F.; Sederias, Joana; Xu, Hao; et al.